Overview
Consumer healthcare firm's Q3 revenue slightly beat analyst expectations
Adjusted EPS for Q3 met analyst expectations
Company closed acquisition of Pillar5 Pharma and repurchased 0.8 mln shares
Outlook
Prestige narrows fiscal 2026 revenue outlook to approximately $1.1 bln
Company maintains fiscal 2026 free cash flow forecast of $245 mln or more
Prestige expects supply improvements for Clear Eyes to support long-term demand
Result Drivers
CLEAR EYES® SUPPLY ISSUES - Revenue decline driven by limited ability to supply demand for Clear Eyes®, impacting Ear & Eye Care sales
PILLAR5 ACQUISITION - Completed acquisition of Pillar5 Pharma, expected to improve eye care supply chain
SHARE REPURCHASE - Repurchased 0.8 mln shares in Q3, leveraging strong free cash flow and low leverage
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Slight Beat*
$283.44 mln
$282.01 mln (7 Analysts)
Q3 Adjusted EPS
Meet
$1.14
$1.14 (7 Analysts)
Q3 Net Income
$46.70 mln
Q3 Gross Profit
$157.37 mln
Q3 Operating Expenses
$74.88 mln
Q3 Operating Income
$82.49 mln
Q3 Pretax Profit
$61.81 mln
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Prestige Consumer Healthcare Inc is $76.00, about 13.4% above its February 4 closing price of $67.03
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago
Press Release: ID:nGNXbvCCgL
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)